Your browser doesn't support javascript.
loading
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
Hammond, Danielle; Loghavi, Sanam; Wang, Sa A; Konopleva, Marina Y; Kadia, Tapan M; Daver, Naval G; Ohanian, Maro; Issa, Ghayas C; Alvarado, Yesid; Short, Nicholas J; Sasaki, Koji; Pemmaraju, Naveen; Montalban-Bravo, Guillermo; Lachowiez, Curtis A; Maiti, Abhishek; Garcia-Manero, Guillermo; Jabbour, Elias J; Borthakur, Gautam; Ravandi, Farhad; Takahashi, Koichi; Pierce, Sherry R; Kantarjian, Hagop M; DiNardo, Courtney D.
Affiliation
  • Hammond D; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Loghavi S; Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Wang SA; Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Konopleva MY; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Kadia TM; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Daver NG; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Ohanian M; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Issa GC; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Alvarado Y; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Short NJ; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Sasaki K; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Pemmaraju N; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Montalban-Bravo G; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Lachowiez CA; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Maiti A; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Garcia-Manero G; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Jabbour EJ; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Borthakur G; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Ravandi F; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Takahashi K; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Pierce SR; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Kantarjian HM; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • DiNardo CD; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. cdinardo@mdanderson.org.
Blood Cancer J ; 13(1): 148, 2023 09 21.
Article in En | MEDLINE | ID: mdl-37735426
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Bridged Bicyclo Compounds, Heterocyclic Limits: Humans Language: En Journal: Blood Cancer J Year: 2023 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Bridged Bicyclo Compounds, Heterocyclic Limits: Humans Language: En Journal: Blood Cancer J Year: 2023 Document type: Article Affiliation country: United States Country of publication: United States